Abstract: An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

Abstract: A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R1, R2, R3, R4, R5, R6, Q, R8, and R9 have the same meanings as R1, R2, R3, R4, R5, R6, Q, R8, and R9 in the specification.

Abstract: An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

Abstract: An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

Abstract: An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].

Abstract: The present invention intends to provide a screening of agonist/antagonist and the like. Specifically, the invention provides a method of screening a compound or its salt that alters the binding property between a novel G protein-coupled receptor protein or its salt, and a substance relating to cholesterol metabolism, which comprises using the receptor protein or its salt, which contains the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 14 or SEQ ID NO: 16, and the substance relating to cholesterol metabolism.

Abstract: A compound of the present invention, or a pharmaceutically acceptable salt thereof is indicated by formula (1) below: wherein, R1, R2, R3, R4, R5, R6, Q, R8, and R9 have the same meanings as R1, R2, R3, R4, R5, R6, Q, R8, and R9 in the specification.

Abstract: The present invention is directed to a method for the treatment of cancer via the administration of a pharmaceutical composition, comprising at least one compound of formula (I) or a pharmaceutically acceptable salt of compound (I), in combination with capecitabine, trastuzumab, pertuzumab, cisplatin or irinotecan, or a pharmaceutically acceptable salt thereof, for simultaneous, sequential or separated administration in the treatment of cancer.

Abstract: The present invention provides a human-derived protein or a salt thereof, a DNA encoding the same, a method for determination of ligand to the protein, a screening method/kits for a compound or its salt that alters a binding property between ligand and the protein, and the like. The human-derived protein or a DNA encoding the same of the present invention can be used in (1) determination of ligand to the protein of the present invention, (2) a prophylactic/therapeutic agent for diseases associated with dysfunction of the protein of the present invention, (3) a screening of a compound (agonist, antagonist, etc.) that alters a binding property between the protein and the ligand of the present invention, and the like.

Abstract: The present invention provides a method and equipment for producing a rail, the method and equipment being capable of lowering a bend at an end of a rail effectively and the truncation amount thereof. The present invention is a method for producing a rail, characterized by: cooling a hot-rolled mother rail to an ordinary temperature substantially while the length thereof after the hot rolling is maintained; and thereafter cutting the mother rail simultaneously in a predetermined length with at least three cold-sawing machines. Further, the present invention is equipment for producing a rail, characterized by equipped with: a transfer bed capable of moving a mother rail cooled to an ordinary temperature substantially while the length thereof after hot rolling is maintained in the rolling direction and/or in the direction perpendicular to the rolling direction; and at least three cold-sawing machines disposed in parallel with each other on said transfer bed.

Abstract: The present invention intends to provide a screening of agonist/antagonist and the like. Specifically, the invention provides a method of screening a compound or its salt that alters the binding property between a novel G protein-coupled receptor protein or its salt, and a substance relating to cholesterol metabolism, which comprises using the receptor protein or its salt, which contains the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 14 or SEQ ID NO: 16, and the substance relating to cholesterol metabolism.

Abstract: The present invention aims at providing a useful and novel G protein-coupled receptor protein and DNA thereof.

Abstract: The present invention intends to screen a novel G protein-coupled receptor protein and to elucidate its function.

Abstract: A novel G protein-coupled receptor protein will be screened. Further, the function will be elucidated.

Abstract: DNAs encoding human leukocyte-derived G protein-coupled receptor proteins or salts thereof are useful in: (1) determining ligands; (2) acquiring antibodies and antisera; (3) constructing a recombinant receptor protein expression system; (4) developing a receptor-bound assay system and screening candidate compounds for a drug using the expression system above; (5) designing drugs based on the comparison with ligand receptors having similar structures; (6) reagents in preparing probes, PCR primers, etc. for gene therapy; (7) constructing transgenic animals; (8) drugs such as gene preventives and remedies; etc.

Abstract: The present invention provides a method and equipment for producing a rail, the method and equipment being capable of lowering a bend at an end of a rail effectively and the truncation amount thereof. The present invention is a method for producing a rail, characterized by: cooling a hot-rolled mother rail to an ordinary temperature substantially while the length thereof after the hot rolling is maintained; and thereafter cutting the mother rail simultaneously in a predetermined length with at least three cold-sawing machines. Further, the present invention is equipment for producing a rail, characterized by equipped with: a transfer bed capable of moving a mother rail cooled to an ordinary temperature substantially while the length thereof after hot rolling is maintained in the rolling direction and/or in the direction perpendicular to the rolling direction; and at least three cold-sawing machines disposed in parallel with each other on said transfer bed.

Abstract: The present invention provides a novel G protein-coupled receptor protein or salts thereof, and a polynucleotide encoding the same, which is useful for screening agonist/antagonist and comprises the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1. It also provides a use such as pharmaceuticals.

Abstract: The present invention provides a novel G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 or salts thereof, and a polynucleotide encoding the same. The present invention also provides a use such as pharmaceuticals, etc.

Abstract: The human leukocyte-derived G protein-coupled receptor protein, a nucleic acid encoding the same and its derivative are useful in determining a ligand (an antagonist) to the receptor protein of the present invention, as an agent for the prevention and/or treatment of diseases associated with the dysfunction of the G protein-coupled receptor protein, etc.

Abstract: The invention relates to N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives which are useful as an agent for treating tumors, pharmaceutical compositions including the same, a method of treating tumors and a method of preparing N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives for treating tumors.Compounds of formula (I), ##STR1## wherein R.sup.1 is a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH.sub.2)n--.sup.Y wherein Y is a cyclohexyl radical, a C.sub.1 -C.sub.4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4, and when Y is C.sub.1 -C.sub.4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R.sup.2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions,or a hydrate or solvate thereof.